NRx & TRx: Prescribing Activity
收藏Databricks2024-05-09 收录
下载链接:
https://marketplace.databricks.com/details/23a63f74-620b-4aa6-8497-fe8369cd3562/Definitive-Healthcare_NRx-&-TRx:-Prescribing-Activity
下载链接
链接失效反馈官方服务:
资源简介:
**Overview**
Turn prescription claims into commercial momentum. Our NRx and TRx dataset provides year-over-year and month-over-month visibility into US physician behavior at the National Drug Code (NDC) level. From tracking launch success to identifying key prescribers, this intelligence empowers you to uncover the exact market drivers that accelerate product performance.
**High Impact Use cases**
- *Launch Velocity Benchmarking*: Analyze new prescriptions at the NDC level to track market adoption and compare your product’s launch trajectory against historical competitor curves.
- *Territory Level Market Share Analysis*: Total prescriptions volume by geography to identify dominant market leaders and reallocate sales resources to high-opportunity territories.
- *Physician Prescribing Habit Profiling*: Segment healthcare practitioners by prescribing habits to distinguish trendsetters who start new patients and caregivers who manage long-term refills.
- *Patient Loyalty & Persistence Tracking*: Compare the ratio of new starts to total refills to see if patients are sticking with your treatment or dropping off.
- *Generic Competition Monitoring*: Watch for shifts in total volume to see exactly how much of your business is being lost to cheaper generic alternatives as soon as they hit the market.
**Product details**
*Sample Tables*:
- Yearly new and total prescribing volume by healthcare provider (HCP) starting in 2016
- Monthly new and total prescribing volume by healthcare provider (HCP) starting in 2016
*Fields Included*:
- Claim year (or Claim month)
- HCP NPI
- National Drug Code (NDC)
- NRx Count
- TRx Count
- Date Updated
Ready to transform your strategy?
To unlock the full power of Definitive Healthcare’s data, please engage with our team: databricks@definitivehc.com.
提供机构:
Definitive Healthcare



